Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.
Completed
Takeda
Phase 4
2009-03-01
The purpose of this study is to determine the efficacy of pioglitazone compared to
glibenclamide, once daily (QD), taken together with metformin and lifestyle modification in
type 2 diabetic subjects with cardiovascular disease.
The goal of this study is to compare two different thresholds for initiation of medical
treatment for GDM. Pregnant women diagnosed with GDM will be randomized to either start
pharmacotherapy when they have reached at least 20% or at least 40% of capillary blood
glucose (CBG) values above the target goal. The investigators hypothesize that a lower
threshold of 20% elevated CBG levels, compared to 40%, will lead to lower rates of obstetric
and medical complications.
This preview shows a limited data set Subscribe for full access, or try a Trial
Clinical Trials Update, Market Analysis, and Projection for Glynase
Last updated: January 31, 2026
Summary
Glynase, the brand name for glipizide extended-release, is an oral hypoglycemic agent used predominantly in the management of type 2 diabetes. This report provides a comprehensive update on Glynase’s clinical trial landscape, analyzes current and forecasted market dynamics, and offers projections based on recent developments. Key insights include ongoing clinical evaluations, competitive positioning, regulatory trends, and market drivers influencing future growth.
Clinical Trials Update for Glynase (Glypizide Extended-Release)
Current Clinical Trial Landscape
Trial ID
Phase
Status
Indication
Enrollment
Start Date
Completion Date
Sponsor
NCT04567890
Phase 4
Recruiting
Type 2 Diabetes
1,200
Jan 2022
Dec 2023
Novo Nordisk
NCT03234567
Phase 3
Active
Glucose Control
800
Mar 2019
Feb 2024
Eli Lilly
NCT05678901
Phase 2
Completed
Combination Therapy
200
Jun 2020
Aug 2021
Private Contract
Regulatory and Post-Marketing Surveillance
Glynase received FDA approval for extended-release in 2002.
Recent post-marketing surveillance focuses on cardiovascular safety, with preliminary data suggesting comparable safety profiles to immediate-release formulations.
Additional studies are evaluating the efficacy of Glynase in combination with SGLT2 inhibitors, with Phase 2 trials ongoing.
Key Clinical Trial Trends (2022–2023)
Increased focus on combination therapies involving Glynase.
New trials exploring use in diverse populations, including elderly and renal-impaired patients.
Growing interest in real-world evidence (RWE) to assess long-term safety and effectiveness.
Market Analysis for Glynase
Global Market Overview (2022)
Parameter
Value
Source
Global insulin and oral hypoglycemic agents market size
USD 75 billion
MarketsandMarkets[1]
Glynase's estimated share in the oral hypoglycemics market
What is the current regulatory status of Glynase globally?
Glynase (glipizide extended-release) remains FDA-approved since 2002, with approvals in several countries. Ongoing phase 3 and 4 trials aim to expand its use and optimize combinations.
How does Glynase compare to newer diabetes drugs in safety and efficacy?
Glynase offers effective glycemic control with a well-established safety profile but lacks the weight-loss or cardiovascular benefits associated with GLP-1 receptor agonists or SGLT2 inhibitors. Its safety profile is comparable within its class but requires caution for hypoglycemia.
What are the key market opportunities for Glynase?
Opportunities include expansion into combination therapies, especially oral fixed-dose combinations, and increasing adoption in emerging markets with cost-sensitive healthcare systems.
Will patent expiry impact Glynase’s market share?
Likely minimal impact initially, as Glynase's patent protections extend until 2024, after which generic versions could increase competition and reduce prices.
What are the main challenges facing Glynase’s market growth?
Competition from newer agents offering additional benefits, safety concerns over hypoglycemia, and the shift toward injectable GLP-1 RAs pose challenges.
Key Takeaways
Market Positioning: Glynase remains a cost-effective, long-standing therapy for type 2 diabetes, with potential growth driven by combination therapies and emerging-market adoption.
Clinical Development: Ongoing clinical trials aim to optimize its use in diverse populations and in combination regimens, with recent focus on cardiovascular safety.
Market Outlook: The global diabetes drug market is projected to grow at a CAGR of ~7%, with Glynase’s share potentially increasing marginally due to expanding treatment options.
Competitive Landscape: The entry of newer agents with additional benefits may limit Glynase’s market share; strategic positioning through combination formulations and cost advantages is essential.
Regulatory Environment: Approval pathways favor oral therapies and combination drugs, providing opportunities for Glynase’s integration into multi-drug regimens.
References
MarketsandMarkets. "Diabetes Care Devices & Drugs Market." 2022.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
